Bicalutamide
-
Molecular Structure
Detailed Description
IUPAC NAME-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide
MOLECULAR FORMULA-C18H14F4N2O4S
MOLAR MASS-430.373 g/mol
Bicalutamide is indicated for the treatment of stage D2 metastatic prostate cancer in combination with a luteinizing hormone-releasing hormone analogue or as a monotherapy.[11] It has also been used in clinical trials for ovarian cancer.[12] It has also been used in combination with castration.[13]
Most advanced prostate cancer patients eventually become resistant to antiandrogen including bicalutamide therapy

- Bicalutamide